Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report

HIGHLIGHTS

• What: The authors report the case of a patient with relapsed AML, who received salvage therapy with VEN-HMA and remained in CR after treatment discontinuation.
• Who: CASE REPORT et al. from the Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy have published the research work: Besides, anecdotal cases suggest the possibility of retreating prior responsive patients with the same VEN-based therapy at relapse [ 6 , 7 ], in the Journal: (JOURNAL)

SUMMARY

Dear editor, Venetoclax (VEN) in combination with hypomethylating agents (HMA) revolutionized acute myeloid . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.